News

The Neomorph team has been busy. Read on to learn what we have been up to.

neomorph employee on computer
April 14, 2026
Neomorph to Highlight Progress in Targeted Protein Degradation Science at the American Association for Cancer Research Annual Meeting
April 13, 2026
Neomorph Announces Closing of $100 Million Series B Financing
February 3, 2026
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
January 23, 2025
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
January 14, 2025
Neomorph Announces Appointment of Dr. Klaus Wagner, M.D., Ph.D. as Chief Medical Officer
October 29, 2024
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
August 20, 2024
Neomorph Announces Appointment of Dr. Peter Lebowitz, M.D., Ph.D. to its Board of Directors
February 26, 2024
Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover Novel Molecular Glue Degraders for Cardiometabolic and Rare Diseases
Scroll to Top
Secret Link